Skip to main
RNTX

RNTX Stock Forecast & Price Target

RNTX Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Rein Therapeutics Inc. is positioned favorably with its focus on developing therapies for orphan pulmonary and fibrosis indications, highlighted by its Phase 2-ready assets, LTI-03 and LTI-01, which target unmet medical needs in Idiopathic Pulmonary Fibrosis and loculated pleural effusion, respectively. The observed increase in sRAGE levels in LTI-03 trial participants indicates a positive pharmacodynamic response, reinforcing the product's potential effectiveness. Furthermore, the company's promising pipeline and favorable risk-reward profile could lead to significant market opportunities, especially if it successfully extends its cash runway to support ongoing clinical development.

Bears say

Rein Therapeutics Inc. has experienced a significant decline in its stock value, with shares falling 50% year to date in 2025, contrasting sharply with the 3.5% gain of the XBI index. The company's decision to pause patient enrollments in its U.S. clinical trials has contributed to heightened uncertainty, negatively impacting investor confidence. Additionally, clinical findings suggest that lower levels of soluble Receptor for Advanced Glycation End-products (sRAGE) correlate with poor survival rates in patients with Idiopathic Pulmonary Fibrosis (IPF), raising further concerns regarding the efficacy of its product candidates in this indication.

RNTX has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Rein Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Rein Therapeutics Inc (RNTX) Forecast

Analysts have given RNTX a Strong Buy based on their latest research and market trends.

According to 1 analysts, RNTX has a Strong Buy consensus rating as of Feb 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Rein Therapeutics Inc (RNTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.